Avacta Group PLC
LSE:AVCT

Watchlist Manager
Avacta Group PLC Logo
Avacta Group PLC
LSE:AVCT
Watchlist
Price: 77 GBX 1.32% Market Closed
Market Cap: 336.1m GBX

Operating Margin
Avacta Group PLC

266.6%
Current
-4 249%
Average
-3.9%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
266.6%
=
Operating Profit
-29.6m
/
Revenue
-11.1m

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
UK
Avacta Group PLC
LSE:AVCT
336.1m GBP
267%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-17 527%
US
Abbvie Inc
NYSE:ABBV
395.9B USD
33%
US
Amgen Inc
NASDAQ:AMGN
170.8B USD
34%
US
Gilead Sciences Inc
NASDAQ:GILD
153B USD
39%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
113.3B USD
39%
US
Epizyme Inc
F:EPE
94.1B EUR
-370%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.6B USD
28%
AU
CSL Ltd
ASX:CSL
88.7B AUD
26%
NL
argenx SE
XBRU:ARGX
46.3B EUR
22%
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
54.4B USD
8%
No Stocks Found

Avacta Group PLC
Glance View

Market Cap
336.1m GBX
Industry
Biotechnology

Avacta Group Plc engages in the provision of Affimer reagents for licensing into third-party research and diagnostic products, and creates new Affimer medicines for development in-house and licensing to large pharmaceutical companies. The company is headquartered in Wetherby, West Yorkshire. The company went IPO on 2003-09-08. The firm is focused on developing cancer immunotherapies and diagnostics based on its Affimer and prelCISION platforms. The company has two divisions: Therapeutics and Diagnostics. Avacta’s therapeutics division develops cancer immunotherapies combining its platforms: Affimer biotherapeutics and prelCISION tumor targeted chemotherapy. The Affimer platform is a class of biotherapeutic based on a naturally occurring human protein. Avacta's prelCISION targeted chemotherapy platform releases active chemotherapy in the tumor, which limits the systemic exposure that causes damage to healthy tissues, and thereby improves the overall safety and therapeutic potential of these anti-cancer treatments. Avacta’s diagnostics division utilizes its Affimer platform to develop diagnostics and works with partners world-wide to develop Affimer reagents with the objective of establishing royalty-bearing license deals.

AVCT Intrinsic Value
HIDDEN
Show
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
266.6%
=
Operating Profit
-29.6m
/
Revenue
-11.1m
What is the Operating Margin of Avacta Group PLC?

Based on Avacta Group PLC's most recent financial statements, the company has Operating Margin of 266.6%.

Back to Top